AU3569497A

AU3569497A – Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to grb2 or crk1
– Google Patents

AU3569497A – Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to grb2 or crk1
– Google Patents
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to grb2 or crk1

Info

Publication number
AU3569497A

AU3569497A
AU35694/97A
AU3569497A
AU3569497A
AU 3569497 A
AU3569497 A
AU 3569497A
AU 35694/97 A
AU35694/97 A
AU 35694/97A
AU 3569497 A
AU3569497 A
AU 3569497A
AU 3569497 A
AU3569497 A
AU 3569497A
Authority
AU
Australia
Prior art keywords
polynucleotide
composition
hybridizes
grb2
cells
Prior art date
1996-07-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU35694/97A
Other versions

AU740289B2
(en

Inventor
Ralph B. Arlinghaus
Gabriel Lopez-Berestein
Ana M. Tari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Texas System

Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1996-07-08
Filing date
1997-07-08
Publication date
1998-02-02

1997-07-08
Application filed by University of Texas System
filed
Critical
University of Texas System

1998-02-02
Publication of AU3569497A
publication
Critical
patent/AU3569497A/en

2001-11-01
Application granted
granted
Critical

2001-11-01
Publication of AU740289B2
publication
Critical
patent/AU740289B2/en

2017-07-08
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P35/00—Antineoplastic agents

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P35/00—Antineoplastic agents

A61P35/02—Antineoplastic agents specific for leukemia

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2310/00—Structure or type of the nucleic acid

C12N2310/10—Type of nucleic acid

C12N2310/11—Antisense

C12N2310/111—Antisense spanning the whole gene, or a large part of it

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2310/00—Structure or type of the nucleic acid

C12N2310/30—Chemical structure

C12N2310/31—Chemical structure of the backbone

C12N2310/311—Phosphotriesters

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2799/00—Uses of viruses

C12N2799/02—Uses of viruses as vector

C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Abstract

The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crk1 nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.

Description

DESCRIPTION
INHIBITION OF CHRONIC MYELOGENOUS LEUKEMIC CELL GROWTH BY LIPOSOMAL-ANTISENSE OLIGODEOXY-NUCLEOTIDES TARGETING
TO Grb2 OR Crkl
BACKGROUND OF THE INVENTION
A. Field of the Invention
The present invention relates to the field of cancer therapy, specifically, the treatment of chronic myelogenous leukemia. More particularly, these treatments involve the use of antisense oligonucleotides and liposomal formulations thereof.
B. Related Art
Chronic myelogenous leukemia (CML) is a hematologic malignancy in which uncontrolled proliferation of granulocytes occurs. It often is characterized by the reciprocal translocation of chromosomes 9 and 22, which relocates the Ableson (abl) protooncogene onto the 3′-end of the breakpoint cluster region (bcr). This produces a chimeric bcr-abl gene encoding a p210 cr’a fusion protein, which is tumorigenic and is necessary for the growth of CML cells (Szczylik et al., 1991 : Skorski et al., 1994; Tari et al, 1994; McGahon et at., 1994; Bedi «?t al., 1994).
The bcr-abl protein can autophosphorylate at the 177 tyrosine amino acid found within the first exon of bcr. When phosphorylated, the bcr domain of the bcr-abl protein binds to the SH2 domain of the growth factor receptor-bound protein 2 (Grb2) adaptor protein. Through the SH3 domain, Grb2 binds to the human Son of sevenless 1 (hSosl) GDP/GTP exchange factor resulting -in ras protein activation. The bcr-abl protein can also transphorylate the 177 tyrosine amino acid found within the normal bcr protein. It is believed that when the normal bcr protein becomes tyrosine phosphorylated at amino acid 177, it also will complex with Grb2. When the bcr-abl protein is expressed, the p46 and p52 She (Puil et al., 1994) proteins become tyrosine phosphorylated as well. These She proteins have also been shown to form stable complexes with Grb2. Therefore, Grb2

appears to play a very important role in the tumorigenicity mediated by the bcr-abl protein (Puil et al. , 1994; Pendergast et al. , 1993).
Another adaptor protein, Crk-like (Crkl), also has been found to bind to bcr-abl. Unlike Grb2, Crkl binds to bcr-abl through the abl domain. Through its SH3 domain, Crkl can also bind to hSosl, which again leads to Ras protein activation (ten Hoeve et al.,
1994a and 1994b). Thus, via the Grb2 and Crkl adaptor proteins, the bcr-abl protein has been linked to ras activation, which is known to lead to tumorigenesis. When ras protein expression is inhibited, proliferation of CML cells is also inhibited. Therefore, one of the major pathways in which bcr-abl protein promotes CML proliferation is by activating ras protein (Skorski et al. , 1994; 1995).
Liposomal-antisense oligonucleotides targeted to bcr-abl can reduce proliferation of CIvIL cells. After maximal inhibition (75% growth inhibition and 90% protein inhibition), CML cells can still recover and grow if the liposomal-antisense oligonucleotides are removed from the culture medium. This is likely caused by incomplete inhibition of bcr-abl protein synthesis Tari et al., 1994). Thus, despite the ability of antisense oligonucleotides to inhibit proliferation of CML cells, there remains a need for more effective compositions and treatments against this form of cancer.
SUMMARY OF THE INVENTION
The present invention is designed to overcome the shortcomings of the prior art by providing improved compositions and methods for the treatment of CML. In particular, the present invention makes use of novel antisense oligonucleotides to target specific nucleic acids in the cells of CML patients.
Thus, in one embodiment, there is provided a composition comprising a polynucleotide that hybridizes to a Grb2-encoding polynucleotide. In another embodiment, there is provided a composition comprising a polynucleotide that hybridizes to a Crkl-encoding polynucleotide. These polynucleotides may be oligonucleotides having a length of 8-50 bases. In a further embodiment, the polynucleotide hybridizes to the translation initiation site of Grb2 mRNA or Crkl mRNA. In specific embodiments, the polynucleotide is an oligonucleotide having the sequence ATATTTGGCGATGGCTTC or GTCGAACCGGCGGAGGA. In another

embodiment, the polynucleotide is encapsulated in a liposome. The liposome may advantageously be comprised of the lipid dioleoylphosphatidylcholine.
In yet another embodiment, there is provided a composition comprising (i) a polynucleotide that hybridizes to a Grb2-encoding polynucleotide or (ii) a polynucleotide that hybridizes to a Crkl-encoding polynucleotide. The composition may further comprise a polynucleotide that hybridizes to a txr-αW-encoding polynucleotide.
In still yet another embodiment, there is provided a composition comprising an expression construct that encodes a first polynucleotide that hybridizes to a Grb2, encoding polynucleotide, wherein said first polynucleotide is under the control of a promoter that is active in eukaryotic cells. Similarly, there is provided a composition comprising an expression construct that encodes a first polynucleotide that hybridizes to a Crkl-encoding polynucleotide, wherein said first polynucleotide is under the control of a promoter that is active in eukaryotic cells.
In still yet another embodiment, there is provided a method for inhibiting proliferation of a cancer cell comprising contacting said cancer cell with a composition comprising at least (i) a polynucleotide that hybridizes to a Grb2 nucleic acid or (ii) a polynucleotide that hybridizes to a Crkl nucleic acid. The polynucleotides may be oligonucleotides having a length of 8-50 bases. The method may further comprise contacting the cancer cell with a composition comprising a polynucleotide that hybridizes to a bcr-abl nucleic acid. The composition may comprise both (i) a polynucleotide that hybridizes to a Grb2 nucleic acid or (ii) a polynucleotide that hybridizes to a Crkl nucleic acid.
The above method may be applied advantageously to a cancer cell that is a leukemia cell or, more specifically, a chronic myelogenous leukemia cell. The composition may comprise a liposome in which the polynucleotide is encapsulated. In a specific embodiment, the contacting takes place in a patient. The patient may be a human. The composition may advantageously be delivered to a human patient in a volume of 0.50-10.0 ml per dose or in an amount of 5-30 mg polynucleotide per m . In a particular regimen, the composition is administered three times per week for eight weeks. Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that

the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein:
FIG. 1 : Effects of Liposomal Antisense Oligonucleotides Specific for Grh2 on Leukemic Cell Growth. BV173, K562 and HL60 cells were incubated with increasing concentrations of liposomal-antisense oligonucleotides specific for Grb2. After three days of incubation, an alamarBlue assay was done to determine the growth-inhibitory effects of these oligonucleotides on the leukemic cells. Viability was expressed as a percentage of untreated cells, which was determined by (absorbance of treated cells/absorbance of untreated cells) X 100.
FIG. 2: Effects of Liposomal Antisense Oligonucleotides Specific for Crkl on Leukemic Cell Growth. BV173, K562 and HL60 cells were incubated with increasing concentrations of liposomal-antisense oligonucleotides specific for Crkl. After three days of incubation, an alamarBlue assay was done to determine the growth-inhibitory effects of these oligonucleotides on the leukemic cells. Viability was expressed as a percentage of untreated cells, which was determined by (absorbance of treated cells/absorbance of untreated cells) X 100. FIG. 3: Effects of Liposomal Control Oligonucleotides on Leukemic Cell
Growth. BV173, K562 and HL60 cells were incubated with increasing concentrations of liposomal-control oligonucleotides. After three days of incubation, an alamarBlue assay was done to determine the growth-inhibitory effects of these oligonucleotides on the leukemic cells. Viability was expressed as a percentage of untreated cells, which was determined by (absorbance of treated cells)/(absorbance of untreated cells) X 100.

FIG. 4: cDNA and Protein Sequence of GRB2. 5′- and 3′-untranslated flanking sequences are illustrated along with the coding region and amino acid sequence. SH2 (thick line) and SH3 (thin line) domains are indicated.
FIG. 5: cDNA and Protein Sequence of CRKL. 5 ‘- and 3′-untranslated flanking sequences are illustrated along with the coding region and amino acid sequence. SH2.
SH2′, SH3 and SH4 domains are indicated by underlining.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
A. The Present Invention Chronic myeloid leukemia, or CML, is a clonal disorder in which the leukemic stem cell gives rise to red cells, neutrophils, eosinophils, basophils, monocyte- macrophages, platelets, T cells and B cells. A reciprocal translocation between chromosomes 9 and 22 results in a shortened chromosome 22, called the Philadelphia chromosome (Ph1). Although up to 10% of CML cases had been classified as Ph negative, such cases are now considered very rare.
This translocation generates a fused gene bcr-abl, the product of which (p210) plays an important role in tumorigenesis. This cytoplasmic protein has about 1910 amino acid residues and includes exons 2 and 3 of bcr and exon 2 of abl. Despite efforts directed at inhibiting the synthesis of bcr-abl using antisense constructs, it appears that the tumorigenic phenotype of Ph positive cells returns shortly after treatments.
The present invention relates to antisense oligonucleotides and polynucleotides directed to portions of the Grb2 and Crkl genes and their use in the treatment of cancer. It is believed that the Grb2 and Crkl gene products both interact with the bcr-abl product and, therefore, participate in the transformation of CML cells. Inhibiting the synthesis of these molecules reduces rumor cell growth. In particular, it is contemplated that using these antisense molecules, either alone or in conjunction with other antisense molecules, it is possible to effectively treat CML, and possibly other cancers. The oligo- or polynucleotides themselves, or expression vectors encoding therefor, may be employed. The preferred method of delivering these nucleic acids is via liposomes. The invention, in its various embodiments, is described in greater detail, below.

B. Polynucleotides and Oligonucleotides
The term «antisense» is intended to refer to polynucleotide molecules complementary to a portion of a Grb2 or Crkl RNA, or the DNA’s corresponding thereto. See FIGS. 4 and 5. «Complementary» polynucleotides are those which are capable of base-pairing according to the standard Watson-Crick complementarity rules. That is, the larger purines will base pair with the smaller pyrimidines to form combinations of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA. Inclusion of less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and others in hybridizing sequences does not interfere with pairing.
Targeting double-stranded (ds) DNA with polynucleotides leads to triple-helix formation; targeting RNA will lead to double-helix formation. Antisense polynucleotides, when introduced into a target cell, specifically bind to their target polynucleotide and interfere with transcription, RNA processing, transport, translation and/or stability. Antisense RNA constructs, or DNA encoding such antisense RNA’s, may be employed to inhibit gene transcription or translation or both within a host cell, either in vitro or in vivo, such as within a host animal, including a human subject.
The intracellular concentration of monovalent cation is approximately 160 mM (10 mM Na+; 150 mM K+). The intracellular concentration of divalent cation is approximately 20 mM (18 mM Mg ; 2 mM Ca+ ). The intracellular protein concentration, which would serve to decrease the volume of hybridization and, therefore, increase the effective concentration of nucleic acid species, is 150 mg/ml. Constructs can be tested in vitro under conditions that mimic these in vivo conditions.
Antisense constructs may be designed to bind to the promoter and other control regions, exons, introns or even exon-intron boundaries of a gene. It is contemplated that the most effective antisense constructs for the present invention will include regions complementary to the mRNA start site. One can readily test such constructs simply by testing the constructs in vitro to determine whether levels of the target protein are affected. Similarly, detrimental non-specific inhibition of protein synthesis also can be measured by determining target cell viability in vitro.

As used herein, the terms «complementary» or «antisense» mean polynucleotides that are substantially complementary over their entire length and have very few base mismatches. For example, sequences of fifteen bases in length may be termed complementary when they have a complementary nucleotide at thirteen or fourteen nucleotides out of fifteen. Naturally, sequences which are «completely complementary» will be sequences which are entirely complementary throughout their entire length and have no base mismatches.
Other sequences with lower degrees of homology also are contemplated. For example, an antisense construct which has limited regions of high homology, but also contains a non-homologous region (e.g., a ribozyme) could be designed. These molecules, though having less than 50% homology, would bind to target sequences under appropriate conditions.
The polynucleotides according to the present invention may encode an Grb2 or Crkl gene or a portion of those genes that is sufficient to effect antisense inhibition of protein expression. The polynucleotides may be derived from genomic DNA, i.e., cloned directly from the genome of a particular organism. In other embodiments, however, the polynucleotides may be complementary DNA (cDNA). cDNA is DNA prepared using messenger RNA (mRNA) as template. Thus, a cDNA does not contain any interrupted coding sequences and usually contains almost exclusively the coding region(s) for the corresponding protein. In other embodiments, the antisense polynucleotide may be produced synthetically.
It may be advantageous to combine portions of the genomic DNA with cDNA or synthetic sequences to generate specific constructs. For example, where an intron is desired in the ultimate construct, a genomic clone will need to be used. The cDNA or a synthesized polynucleotide may provide more convenient restriction sites for the remaining portion of the construct and, therefore, would be used for the rest of the sequence.
The DNA and protein sequences for Grb2 and Crkl are published in the literature by Lowenstein et al. (1992) and ten Hoeve et al. (1993), respectively, both of which are incoφorated herein by reference. It is contemplated that natural variants of exist that have different sequences than those disclosed herein. Thus, the present invention is not

limited to use of the provided polynucleotide sequence for Grb2 and Crkl but, rather, includes use of any naturally-occurring variants. Depending on the particular sequence of such variants, they may provide additional advantages in terms of target selectivity, i.e.. avoid unwanted antisense inhibition of related transcripts. The present invention also encompasses chemically synthesized Mutants of these sequences.
As stated above, although the antisense sequences may be full length genomic or cDNA copies (see FIGS. 4 and 5), or large fragments thereof, they also may be shorter fragments, or «oligonucleotides,» defined herein as polynucleotides of 50 or less bases. Although shorter oiigomers (8-20) are easier to make and increase in vivo accessibility, numerous other factors are involved in determining the specificity of base-pairing. For example, both binding affinity and sequence specificity of an oligonucleotide to its complementary target increase with increasing length. It is contemplated that oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45 or 50 base pairs will be used. While all or part of the gene sequence may be employed in the context of antisense construction, statistically, any sequence of 17 bases long should occur only once in the human genome and, therefore, suffice to specify a unique target sequence.
In certain embodiments, one may wish to employ antisense constructs which include other elements, for example, those which include C-5 pyrimidines. Oligonucleotides which contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and to be potent antisense inhibitors of gene expression (Wagner et al., 1993).
As an alternative to targeted antisense delivery, targeted ribozymes may be used. The term «ribozyme» is refers to an RNA-based enzyme capable of targeting and cleaving particular base sequences in both DNA and RNA. Ribozymes can either be targeted directly to cells, in the form of RNA oligonucleotides incorporating ribozyme sequences, or introduced into the cell as an expression vector encoding the desired ribozymal RNA. Ribozymes may be used and applied in much the same way as described for antisense polynucleotide. Ribozyme sequences also may be modified in much the same way as described for antisense polynucleotide. For example, one could incorporate non-Watson-Crick bases, or make mixed RNA/DNA oligonucleotides, or

modify the phosphodiester backbone, or modify the 2′-hydroxy in the ribose sugar group of the RNA.
Alternatively, the antisense oligo- and polynucleotides according to the present invention may be provided as RNA via transcription from expression constructs that carry nucleic acids encoding the oligo- or polynucleotides. Throughout this application, the term «expression construct» is meant to include any type of genetic construct containing a nucleic acid encoding an antisense product in which part or all of the nucleic acid sequence is capable of being transcribed. Typical expression vectors include bacterial plasmids or phage, such as any of the pUC or Bluescript™ plasmid series or, as discussed further below, viral vectors adapted for use in eukaryotic cells.
In preferred embodiments, the nucleic acid encodes an antisense oligo- or polynucleotide under transcriptional control of a promoter. A «promoter» refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrase «under transcriptional control» means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation.
The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins. At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation. Additional promoter elements regulate the frequency of transcriptional initiation.
Typically, these are located in the region 30-110 bp upstream of the start site, although a

number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.
The particular promoter that is employed to control the expression of a nucleic acid encoding the inhibitory peptide is not believed to be important, so long as it is capable of expressing the peptide in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding the inhibitory peptide adjacent to and under the control of a promoter that is active in the human cell. Generally speaking, such a promoter might include either a human or viral promoter.
In various embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter and the Rous sarcoma virus long terminal repeat can be used to obtain high-level expression of various proteins. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of peptides according to the present invention is contemplated as well, provided that the levels of expression are sufficient for a given purpose. By employing a promoter with well-known properties, the level and pattern of expression of an antisense oligo- or polynucleotide can be optimized. Further, selection of a promoter that is regulated in response to specific physiologic signals can permit inducible expression of an inhibitory protein. For example, a nucleic acid under control of the human PAI-1 promoter results in expression inducible by tumor necrosis factor. Tables 2 and 3 list several elements/promoters which may be employed, in the context of the present invention, to regulate the expression of antisense constructs. This list is not intended to be exhaustive of all the possible elements involved in the promotion of expression but, merely, to be exemplary thereof.
Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA.
This ability to act over a large distance had little precedent in classic studies of

prokaryotic transcriptional regulation. Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.
The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.
Below is a list of viral promoters, cellular promoters/enhancers and inducible promoters/enhancers that could be used in combination with the nucleic acid encoding an NF-IL6 inhibitory peptide in an expression construct (Table 1 and Table 2). Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) also could be used to drive expression of a nucleic acid according to the present invention. Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.

TABLE 1
PROMOTER
Immunoglobulin Heavy Chain
Immunoglobulin Light Chain
T-Cell Receptor
HLA DQ αand DQ β β-Intefferon
Interleukin-2
Interleukin-2 Receptor
MHC Class II 5
MHC Class II HLA-DRα β-Actin
Muscle Creatine Kinase
Prealbumin (Transthyretin)
Elastase /
Metallothionein
Collagenase
Albumin Gene α-Fetoprotein
©-Globin β-Globin c-fos c-HA-ras
Insulin
Neural Cell Adhesion Molecule (NCAM) α 1 -Antitrypsin
H2B (TH2B) Histone
Mouse or Type I Collagen
Glucose-Regulated Proteins (GRP94 and GRP78)
Rat Growth Hormone
Human Serum Amyloid A (SAA)
Troponin I (TN I)
Platelet-Derived Growth Factor
Duchenne Muscular Dystrophy
SV40
Polyoma
Retroviruses
Papilloma Virus
Hepatitis B Virus
Human Immunodeficiency Virus
Cytomegalovirus
Gibbon Ape Leukemia Virus

TABLE 2
Element MT II Inducer
MT U Phorbol Ester (TPA) Heavy metals
MMTV (mouse mammary tumor virus) Glucocorticoids β-Interferon poly(rI)X poly(rc)
Adenovirus 5 E2 Ela c-jun Phorbol Ester (TPA), H202
Collagenase Phorbol Ester (TPA)
Stromelysin Phorbol Ester (TPA), IL-1
SV40 Phorbol Ester (TPA)
Murine MX Gene Interferon, Newcastle Disease Virus
GRP78 Gene A23187 α-2-Macroglobulin IL-6
Vimentin Serum
MHC Class I Gene H-2kB Interferon
HSP70 Ela, SV40 Large T Antigen
Proliferin Phorbol Ester (TPA)
Tumor Necrosis Factor PHA
Thyroid Stimulating Hormone α Gene Thyroid Hormone
In certain embodiments of the invention, the delivery of a nucleic acid in a cell may be identified in vitro or in vivo by including a marker in the expression construct. The marker would result in an identifiable change to the transfected cell permitting easy identification of expression. Enzymes such as herpes simplex virus thymidine kinase (tk) (eukaryotic) or chloramphenicol acetyltransferase (CAT) (prokaryotic) may be employed.
One also may include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to

the successful practice of the invention, and any such sequence may be employed. For example, the SV40, β-globin or adenovirus polyadenylation signal may be employed. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.
C. Liposomal Formulations
In a preferred embodiment of the invention, the antisense oligo- or polynucleotides and expression vectors may be entrapped in a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991 ). Also contemplated are cationic lipid-nuclcic acid complexes, such as lipofectamine-nucleic acid complexes.
Liposome-mediated polynucleotide delivery and expression of foreign DNA in vitro has been very successful. Wong et al. (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells. Nicolau et al. (1987) accomplished successful liposome- mediated gene transfer in rats after intravenous injection.
In certain embodiments of the invention, the liposome may be complexed with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda et al., 1989). In other embodiments, the liposome may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG- 1 ) (Kato et al., 1991 ). In yet further embodiments, the liposome maybe complexed or employed in conjunction with both HVJ and HMG-1. In that such expression vectors have been successfully employed in transfer and expression of a polynucleotide in vitro and in vivo, then they are applicable for the present invention. Where a bacterial promoter is employed in the DNA construct, it also will be desirable to include within the liposome an appropriate bacterial polymerase.

«Liposome» is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers. Phospholipids are used for preparing the liposomes according to the present invention and can carry a net positive charge, a net negative charge or are neutral. Directly phosphate can be employed to confer a negative charge on the liposomes, and stearylamine can be used to confer a positive charge on the liposomes.
Lipids suitable for use according to the present invention can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine («DMPC») can be obtained from Sigma Chemical Co., dicetyl phosphate («DCP») is obtained from K & K Laboratories (Plainview, NY); cholesterol («Choi») is obtained from Calbiochem-
Behring; dimyristyl phosphatidylglycerol («DMPG») and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, Ala.). Stock solutions of lipids in chloroform, chloroform/methanol or t-butanol can be stored at about -20°C. Preferably, chloroform is used as the only solvent since it is more readily evaporated than methanol. Phospholipids from natural sources, such as egg or soybean phosphatidylcholine, brain phosphatidic acid, brain or plant phosphatidylinositol, heart cardiolipin and plant or bacterial phosphatidylethanolamine are preferably not used as the primary phosphatide, i.e., constituting 50% or more of the total phosphatide composition, because of the instability and leakiness of the resulting liposomes. Liposomes used according to the present invention can be made by different methods. The size of the liposomes varies depending on the method of synthesis. A liposome suspended in aqueous solution is generally in the shape of a spherical vesicle, having one or more concentric layers of lipid bilayer molecules. Each layer consists of a parallel array of molecules represented by the formula XY, wherein X is a hydrophilic moiety and Y is a hydrophobic moiety. In aqueous suspension, the concentric layers are arranged such that the hydrophilic moieties tend to remain in contact with an aqueous phase and the hydrophobic regions tend to self-associate. For example, when aqueous phases are present both within and without the liposome, the lipid molecules will form a bilayer, known as a lamella, of the arrangement XY-YX. Liposomes within the scope of the present invention can be prepared in accordance with known laboratory techniques. In one preferred embodiment, liposomes

are prepared by mixing liposomal lipids, in a solvent in a container, e.g., a glass, pear- shaped flask. The container should have a volume ten-times greater than the volume of the expected suspension of liposomes. Using a rotary evaporator, the solvent is removed at approximately 40°C under negative pressure. The solvent normally is removed within about 5 min to 2 hours, depending on the desired volume of the liposomes. The composition can be dried further in a desiccator under vacuum. The dried lipids generally are discarded after about 1 week because of a tendency to deteriorate with time. Dried lipids can be hydrated at approximately 25-50 mM phospholipid in sterile, pyrogen-free water by shaking until all the lipid film is resuspended. The aqueous liposomes can be then separated into aliquots, each placed in a vial, lyophilized and sealed under vacuum.
In the alternative, liposomes can be prepared in accordance with other known laboratory procedures: the method of Bangham et αl. (1965), the contents of which are incorporated herein by reference; the method of Gregoriadis, as described in DRUG CARRIERS IN BIOLOGY AND MEDICINE, G. Gregoriadis ed. ( 1979) pp. 287-341 , the contents of which are incoφorated herein by reference; the method of Deamer and Ustet (1983), the contents of which are incoφorated by reference; and the reverse-phase evaporation method as described by Szoka and Papahadjopoulos (1978). The aforementioned methods differ in their respective to entrap aqueous material and their respective and space-to-lipid ratios.
The dried lipids or lyophilized liposomes prepared as described above may be reconstituted in a solution of nucleic acid and diluted to an appropriate concentration with an suitable solvent, e.g., DPBS. The mixture is then vigorously shaken in a vortex mixer. Unencapsulated nucleic acid is removed by centrifugation at 29.000 x g and the liposomal pellets washed. The washed liposomes are resuspended at an appropriate total phospholipid concentration, e.g., about 50-200 mM. The amount of nucleic acid encapsulated can be determined in accordance with standard methods. After determination of the amount of nucleic acid encapsulated in the liposome preparation, the liposomes may be diluted to appropriate concentration and stored at 4°C until use. In a preferred embodiment, the lipid dioleoylphosphatidylchoine is employed.
Nuclease-resistant oligonucleotides were mixed with lipids in the presence of excess t-

bntanol. The mixture was vortexed before being frozen in an acetone/dry ice bath. The frozen mixture was lyophilized and hydrated with Hepes-buffered saline ( 1 mM Hepcs, 10 mM NaCl, pH 7.5) overnight, and then the liposomes were sonicated in a bath type sonicator for 10 to 15 min. The size of the liposomal-oligonucleotides typically ranged between 200-300 nm in diameter as determined by the submicron particle sizer autodilute model 370 (Nicomp, Santa Barbara, CA).
D. Alternative Delivery Systems
Retroviruses. The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes – gag, pol, and env – that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene, termed ψ, functions as a signal for packaging of the genome into virions. Two long terminal repeat (LTR) sequences are present at the 5′ and 3′ ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990). In order to construct a retroviral vector, a nucleic acid encoding a Grb2 or Crkl antisense construct is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the gag, pol and env genes but without the LTR and ^ components is constructed (Mann et al, 1983). When a recombinant plasmid containing an inserted DNA, together with the retroviral LTR and • sequences, is introduced into this cell line (by calcium phosphate precipitation for example), the ■ sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann et at, 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a

broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind et al, 1975).
Adenoviruses: Human adenoviruses are double-stranded DNA tumor viruses with genome sizes of approximate 36 kB (Tooze, 1981 ). As a model system for eukaryotic gene expression, adenoviruses have been widely studied and well characterized, which makes them an attractive system for development of adenovirus as a gene transfer system. This group of viruses is easy to grow and manipulate, and they exhibit a broad host range in vitro and in vivo. In lytically infected cells, adenoviruses are capable of shutting off host protein synthesis, directing cellular machineries to synthesize large quantities of viral proteins, and producing copious amounts of virus.
The El region of the genome includes El A and E1 B which encode proteins responsible for transcription regulation of the viral genome, as well as a few cellular genes. E2 expression, including E2A and E2B, allows synthesis of viral replicative functions, e.g. DNA-binding protein, DNA polymerase, and a terminal protein that primes replication. E3 gene products prevent cytolysis by cytotoxic T cells and rumor necrosis factor and appear to be important for viral propagation. Functions associated with the E4 proteins include DNA replication, late gene expression, and host cell shutoff. The late gene products include most of the virion capsid proteins, and these are expressed only after most of the processing of a single primary transcript from the major late promoter has occurred. The major late promoter (MLP) exhibits high efficiency during the late phase of the infection (Stratford-Perricaudet and Perricaudet, 1991 ).
As only a small portion of the viral genome appears to be required in cis (Tooze, 1981 ), adenovirus-derived vectors offer excellent potential for the substitution of large DNA fragments when used in connection with cell lines such as 293 cells. Ad5- transformed human embryonic kidney cell lines (Graham, et al, 1977) have been developed to provide the essential viral proteins in trans.
Particular advantages of an adenovirus system for delivering foreign proteins to a cell include (i) the ability to substitute relatively large pieces of viral DNA by foreign DNA; (ii) the structural stability of recombinant adenoviruses; (iii) the safety of adenoviral administration to humans; and (iv) lack of any known association of

adenoviral infection with cancer or malignancies; (v) the ability to obtain high titers of the recombinant virus; and (vi) the high infectivity of adenovirus.
Further advantages of adenovirus vectors over retroviruses include the higher levels of gene expression. Additionally, adenovirus replication is independent of host gene replication, unlike retroviral sequences. Because adenovirus transforming genes in the El region can be readily deleted and still provide efficient expression vectors, oncogenic risk from adenovirus vectors is thought to be negligible (Grunhaus & Horwitz. 1992).
In general, adenovirus gene transfer systems are based upon recombinant, engineered adenovirus which is rendered replication-incompetent by deletion of a portion of its genome, such as El, and yet still retains its competency for infection. Sequences encoding relatively large foreign proteins can be expressed when additional deletions are made in the adenovirus genome. For example, adenoviruses deleted in both El and E3 regions are capable of carrying up to 10 kB of foreign DNA and can be grown to high titers in 293 cells (Stratford-Perricaudet and Perricaudet, 1991). Suφrisingly persistent expression of transgenes following adenoviral infection has also been reported.
Other Viral Vectors as Expression Constructs. Other viral vectors may be employed as expression constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al, 1988) adeno-associated virus (AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986;
Hermonat and Muzycska, 1984) and heφesviruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al, 1988; Horwich et al, 1990).
With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. In vitro studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite the deletion of up to 80% of its genome (Horwich et al, 1990). This suggested that large portions of the genome could be replaced with foreign genetic material. The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer. Chang et al recently introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the

place of the polymerase, surface, and pre-surface coding sequences. It was cotransfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang et al, 1991 ).
Non- viral Methods: Several non-viral methods for the transfer of expression vectors into cultured mammalian cells also are contemplated by the present invention. These include calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe et al, 1990) DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa et al, 1986; Potter et al, 1984), direct microinjection (Harland and
Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley et al, 1979) and lipofectamine-DNA complexes, cell sonication (Fechheimer et al, 1987), gene bombardment using high velocity microprojectiles (Yang et al, 1990), polycations (Boussif et al, 1995) and receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988). Some of these techniques may be successfully adapted for in vivo or ex vivo use.
In one embodiment of the invention, the expression construct may simply consist of naked recombinant vector. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. For example, Dubensky et al. (1984) successfully injected polyomavirus
DNA in the form of CaPO4 precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Neshif (1986) also demonstrated that direct intraperitoneal injection of CaPO precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding an Grb2 or Crkl construct may also be transferred in a similar manner in vivo.
Another embodiment of the invention for transferring a naked DNA expression vector into cells may involve particle bombardment. This method depends on the ability to accelerate DNA coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein et al, 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive

force (Yang et al, 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.
Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded in vivo (Yang et al, 1990; Zelenin et al, 1991). This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ. DNA encoding a Grb2 or Crkl construct may be delivered via this method.
E. Pharmaceutical Compositions and Routes of Administration
Where clinical application of liposomes containing antisense oligo- or polynucleotides or expression vectors is undertaken, it will be necessary to prepare the liposome complex as a pharmaceutical composition appropriate for the intended application. Generally, this will entail preparing a pharmaceutical composition that is essentially free of pyrogens, as well as any other impurities that could be harmful to humans or animals. One also will generally desire to employ appropriate buffers to render the complex stable and allow for uptake by target cells.
Aqueous compositions of the present invention comprise an effective amount of the antisense expression vector encapsulated in a liposome as discussed above, further dispersed in pharmaceutically acceptable carrier or aqueous medium. Such compositions also are referred to as inocula. The phrases «pharmaceutically or pharmacologically acceptable» refer to compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
As used herein, «pharmaceutically acceptable carrier» includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absoφtion delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incoφorated into the compositions.
Solutions of therapeutic compositions can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, mixtures thereof and in oils. Under ordinary

conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The therapeutic compositions of the present invention are advantageously administered in the form of injectable compositions either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. These preparations also may be emulsified. A typical composition for such puφose comprises a pharmaceutically acceptable carrier. For instance, the composition may contain 10 mg, 25 mg, 50 mg or up to about 100 mg of human sertun albumin per milliliter of phosphate buffered saline. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like.
Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate. Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer’s dextrose, etc. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial agents, anti-oxidants, chelating agents and inert gases. The pH and exact concentration of the various components the pharmaceutical composition are adjusted according to well known parameters.
Additional formulations are suitable for oral administration. Oral formulations include such typical excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. The compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders. When the route is topical, the form may be a cream, ointment, salve or spray. The therapeutic compositions of the present invention may include classic pharmaceutical preparations. Administration of therapeutic compositions according to the present invention will be via any common route so long as the target tissue is available via that route. This includes oral, nasal, buccal, rectal, vaginal or topical. Topical administration would be particularly advantageous for treatment of skin cancers, to prevent chemotherapy-induced alopecia or other dermal hypeφroliferative disorder.
Alternatively, administration will be by orthotopic, intradermal subcutaneous.

intramuscular, intraperitoneal or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients. For treatment of conditions of the lungs, the preferred route is aerosol delivery to the lung. Volume of the aerosol is between about 0.01 ml and 0.5 ml. Similarly, a preferred method for treatment of colon-associated disease would be via enema. Volume of the enema is between about 1 ml and 100 ml.
An effective amount of the therapeutic composition is determined based on the intended goal. The term «unit dose» or «dosage» refers to physically discrete units suitable for use in a subject, each unit containing a predetermined-quantity of the therapeutic composition calculated to produce the desired responses, discussed above, in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the protection desired. Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the patient, the route of administration, the intended goal of treatment (alleviation of symptoms versus cure) and the potency, stability and toxicity of the particular therapeutic substance. For the instant application, it is envisioned that the amount of therapeutic composition comprising a unit dose will range from about 5-30 mg of polynucleotide.
F. Clinical Protocols
Typically, patients that are candidates for treatment are those in the chronic phase of CML. About 7,000 new patients per year are diagnosed with CML, and the median duration of the chronic phase of the disease lasts for five years. The typical course of treatment will be given in eight week cycles, although longer duration may be used if no adverse effects are observed with the patient, and shorter terms of treatment may result if the patient does not tolerate the treatment as hoped. Each cycle will consist of between 20 and 35 individual doses spaced equally, although this too may be varied depending on the clinical situation.

G. Examples
EXAMPLE 1 : Synthesis of oligonucleotides.
Nuclease-resistant p-ethoxy oligonucleotides were purchased from Oligos Etc. (Willsonville, OR). The length of the oligonucleotides range between 16 to 18 bases. The sequences of the oligonucleotides, from 5′ to 3’, are as follows:
1. Antisense oligonucleotide targeting the translation initiation site of Grb2: ATATTTGGCGATGGCTTC
2. Antisense oligonucleotide targeting the translation initiation site of Crkl: GTCGAACCGGCGGAGGA
3. Control oligos: GAAGGGCTTCTGCGTC
EXAMPLE 2: Liposome Formation.
The lipid, dioleoylphosphatidylchoine, was purchased from Avanti Polar Lipids, Inc. (Alabaster AL). Nuclease-resistant oligonucleotides were mixed with lipids in the presence of excess t-butanol. The mixture was vortexed before being frozen in an acetone/dry ice bath. The frozen mixture was lyophilized and hydrated with Hepes- buffered saline (1 mM Hepes, 10 mM NaCl, pH 7.5) overnight, and then the liposomes were sonicated in a bath type sonicator for 10 to 15 min. The size of the liposomal- oligonucleotides typically ranged between 200-300 nm in diameter as determined by the submicron particle sizer autodilute model 370 (Nicomp, Santa Barbara, CA).
EXAMPLE 3: Oligonucleotide Inhibition of Cell Proliferation (Grb2
The CML cell lines BV173 and K562 were employed to test the ability of oligonucleotides to inhibit cell growth. These cell lines were originally obtained from human CML patients in blast crisis. Both cell lines express the p210 Bcr»Abl fusion protein. HL60 cells, which were originally obtained from a human promyelocytic patient, were used as a control as these cells do not produce bcr-ab, and their proliferation is independent of the ras-signaling pathway.
Five thousand K562 cells, ten thousand BV173 cells, or ten thousand HL60 cells were plated per well in a 96-well plate in 0.1 mL of RPMI 1640 medium containing 10%

fetal calf serum. After 2 h of plating, final concentrations of 0-10 μM of liposomal- oligonucleotides were added to these cells. The cells were incubated with liposomal- oligonucleotides for 3 days. The effects of the liposomal-oligonucleotides on the proliferation of the leukemic cells were tested by the alamarBlue (Alamar, Sacramento, CA) assay.
AlamarBlue is an oxidation/reduction indicator dye in which absorbency is related to cellular metabolic reduction. Therefore, it is a measure of both cell number and metabolic activity of the cells. After incubation with liposomal-oligonucleotides, 50 μL aliquoted of cells/well were added to 130μL of medium. Twenty μL of alamarBlue dye were added to each well. After incubation for 6-8 h at 37°C, the plates were read directly on a microplate reader (Molecular Devices, Menlo Park, CA) at 570 and 595 nm. The difference in absorbency between 570 and 595 nm was taken as the overall absorbency value of the leukemic cells. The viabilities of liposomal-oligonucleotide- treated cells were compared with those of the untreated cells. Liposomal-antisense oligonucleotides specific for Grb2 can inhibit the proliferation of leukemic cells in a dose-dependent manner. When 5-7μM concentrations of liposomal-antisense oligonucleotides specific for Grb2 were used (FIG. 1), the viabilities of the CML cell lines BV 173 and K562 were 10-60% of that of untreated cells. In other words 40-90%) growth inhibition was induced in CML cells. Under identical conditions, the cell viabilities of HL60 cells were not reduced. In fact, the viabilities of HL60 cells were not reduced until concentrations of 8-10 μM were employed.
EXAMPLE 4: Oligonucleotide Inhibition of Cell Proliferation fCrklY
The assay was conducted as described in Example 5. Liposomal-antisense oligonucleotides specific for Crkl can inhibit the proliferation of leukemic cells in a dose- dependent manner. When 5-8 μM concentrations of liposomal-antisense oligonucleotides specific for Crkl were used (FIG 2), the viabilities of BV173 cells were 10-40% of that of untreated cells. When 8-9 μM concentrations of liposomal-antisense oligonucleotides were used, the viabilities of K562 cells were 10-40% of untreated cells. The cell viabilities of HL60 cells were not reduced to 40%, except when 10 μM concentrations of liposomal-antisense oligonucleotides were used.

EXAMPLE 5: Oligonucleotide Inhibition of Cell proliferation (Control).
Liposomal-control oligonucleotides that do not hybridize to Grb2 or Crkl sequences do not inhibit the proliferation of CML cells except at high concentrations. The viabilities of BV173 cells were reduced by 50% when 8 μM or greater concentrations of liposomal-control oligos were used. The viabilities of K562 and HL60 cells were not reduced except at 10 μM concentrations.

H. References
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incoφorated herein by reference:
Baichwal and Sugden, «Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes,» In: Kucherlapati R, ed. Gene transfer. New York: Plenum Press, pp. 1 17-148, 1986. Bangham et al, J. Mol. Biol. 13:238-52 (1965). Bedi et al, «Inhibition of apoptosis by Bcr-Abl in chronic myeloid leukemia,» Blood
83:2038-2044, 1994. Benvenisty and Neshif, «Direction introduction of genes into rats and expression of the genes,» Proc. Natl. Acad Sci. USA, 83:9551-9555, 1986. Boussif et α/., 1995. Chang et al. , «Foreign gene delivery and expression in hepatocytes using a hepatitis B virus vector,» Hepatology, 14:134A, 1991. Chen and Okayama, «High-efficiency transfection of mammalian cells by plasmid
DNA,» Mol Cell Biol, 7:2745-2752, 1987. Coffin, «Retroviridae and their replication,» In: Virology, Fields et al. (eds.), New York: Raven Press, pp. 1437-1500, 1990.
Coupar et al, «A general method for the construction of recombinant vaccinia virus expressing multiple foreign genes,» Gene, 68:1-10, 1988. Deamer and Uster, 1983.
Dubensky et al, «Direct transfection of viral and plasmid DNA into the liver or spleen of mice,» Proc. Nat’l Acad. Sci. USA, 81 :7529-7533, 1984.
Fechheimer et al, «Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading,» Proc. Nat’l Acad Sci. USA, 84:8463-8467, 1987. Fraley et al, «Entrapment of a bacterial plasmid in phospholipid vesicles: Potential for gene transfer,» Proc. Nat’l Acad. Sci. USA, 76:3348-3352, 1979. Friedmann, «Progress toward human gene therapy,» Science, 244:1275-1281 , 1989.

Ghosh and Bachhawat, «Targeting of liposomes to hepatocytes,» In: Wu G, Wu C ed.,
Liver diseases, targeted diagnosis and therapy using specific receptors and ligands. New York: Marcel Dekker, pp. 87-104, 1991. Gopal, «Gene transfer method for transient gene expression, stable transfection, and cotransfection of suspension cell cultures,» Mol Cell Biol, 5: 1 188-1 190, 1985.
Graham and van der Eb, «A new technique for the assay of infectivity of human adenovirus 5 DNA», Virology, 52:456-467, 1973. Graham et at. , «Characteristics of a human cell line transformed by DNA from human adenovirus type 5», J. Gen. Virol, 36:59-72, 1977. Gregoriadis, Drug Carriers In Biology And Medicine, G. Gregoriadis ed. ( 1979).
Grunhaus and Horwitz, «Adenovirus as cloning vector,» Seminar in Virology, 3:237-252,
1992. Harland and Weintraub, «Translation of mammalian mRNA injected into Xenopus oocytes is specifically inhibited by antisense RNA,» J. Cell Biol , 101 : 1094- 1099, 1985.
Hermonat and Muzycska, «Use of adenoassociated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells,» Proc. Natl. Acad Sci. USA, 81 :6466-6470, 1984. Horwich et al, «Synthesis of hepadenovirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 cells,» J. Virol. 64:642-650,
1990. Kaneda et al, «Increased expression of DNA cointroduced with nuclear protein in adult rat liver,» Science, 243:375-378, 1989. Kato et al. , «Expression of hepatitis B virus surface antigen in adult rat liver,» J. Biol Chem., 266:3361-3364, 1991.
Klein et al, «High-velocity microprojectiles for delivering nucleic acids into living cells,» Nature, 327:70-73, 1987. Lowenstein et al , «The SH2 and SH3 domain-containing protein Grb2 links receptor tyrosine kinases to ras signalling,» Cell, 70:431-442, 1992. Mann et al, «Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus,» Cell, 33:153-159, 1983.

McGahon et al, «Bcr-Abl maintains resistance of chronic myelogneous leukemia cells to apoptotic cell death,» Blood, 83: 1 179-1 187, 1994. Nicolas and Rubenstein, «Retroviral vectors,» In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, pp. 494-513, 1988.
Nicolau et al, «Liposomes as carriers for in vivo gene transfer and expression,» Methods
Enzymol , 149: 157-176, 1987. Nicolau and Sene, «Liposome-mediated DNA transfer in eukaryotic cells,» Biochem.
Biophys. Acta, 721 :185-190, 1982. Paskind et al, «Dependence of moloney murine leukemia virus production on cell growth,» Virology, 67:242-248, 1975. Pendergast et al, «Bcr-Abl-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein,» Cell, 75:175-185. Potter et al, «Enhancer-dependent expression of human k immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation,» Proc. Nat’l Acad.
Sci. t/SΛ, 81 :7161-7165, 1984. Puil et al, «Bcr-Abl oncoproteins bind directly to activators of the ras signaling pathway,» EMBOl, 13(4):764-773, 1994. Ridgeway, «Mammalian expression vectors,» In: Rodriguez RL, Denhardt DT, ed. Vectors: A survey of molecular cloning vectors and their uses. Stoneham:
Butterworth, pp. 467-492, 1988. Rippe et al, «DNA-mediated gene transfer into adult rat hepatocytes in primary culture,»
Mol. Cell Biol, .10:689-695, 1990. Skorski et al, «Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells,» Blood
86:726-736, 1995. Skorski et al, «Negative regulation of pl20SaP GTPase promoting activity by p210^cr-
Abl: Implication for RAS-dependent Philadelphia chromosome positive cell growth,» J. Exp. Med, 179:1855-1865, 1994.

Skorski et al, «Suppression of Philadelphia leukemia cell growth in mice by Bcr-Abl antisense oligodeoxynucleotides,» Proc. Natl. Acad. Sci. USA, 91 :4504-4508,
1994. Stratford- Perricaudet and Perricaudet, «Gene transfer into animals: the promise of adenovirus,» p. 51-61, 7/7. ‘ Human Gene Transfer, Eds, O. Cohen-Haguenauer and
M. Boiron, Editions John Libbey Eurotext, France, 1991. Szoka and Papahadjopoulos, 1978. Szczylik et al, «Selective inhibition of Leukemia cell proliferation by BCR-ABL antisense oligonucleotides,» Science, 253:562-265, 1991. Tari et al, «Liposomal delivery of methylphosphonate oligodeoxynucleotides in chronic myelogenous leukemia,» Blood 84:601 -607, 1994. ten Hoeve et al, «Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia,»
Blood, 84: 173 1-1736, 1994. ten Hoeve et al, «Cellular interactions of CRKL, an SH2-SH3 adaptor protein,» Cancer Res., 54:2563-2567, 1994. ten Hoeve et al, «Isolation and chromosomal localization of CRKL, a human CRK-like gene,» Oncogene, 8:2469-2475, 1993. Temin, «Retrovirus vectors for gene transfer: Efficient integration into and expression of exogenous DNA in vertebrate cell genome,» In: Gene Transfer, Kucherlapati (ed.). New York: Plenum Press, pp. 149- 188, 1986.
Tooze, 1981. Tur-Kaspa et al. , «Use of electroporation to introduce biologically active foreign genes into primary rat hepatocytes,» Mol Cell Biol, 6:716-718, 1986. Wagner et al, Science, 260:1510-1513, 1993. Wong et al, «Appearance of [Beta]-lactamase activity in animal cells upon liposome mediated gene transfer,» Gene, 10:87-94, 1980. Wu and Wu, «Evidence for targeted gene delivery to HepG2 hepatoma cells in vitro,»
Biochemistry, 27 :887 -892, 1988. Wu and Wu, «Receptor-mediated in vitro gene transfections by a soluble DNA carrier system,» d. Biol. Chem., 262:4429-4432, 1987.

Yang et al, «in vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment,» Proc. Nat’l Acad. Sci. USA, 87:9568-9572, 1990.
Zelenin et al. «High-velocity mechanical DNA transfer of the chloramphenicol acetyltransferase gene into rodent liver, kidney and mammary gland cells in organ explants and in vivo,» FEBS Lett., 280:94-96, 1991.

SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Board of Regents, The University of Texas System
(B) STREET: 201 W. 7th Street
(C) CITY: Austin
(D) STATE: Texas
(E) COUNTRY: U.S.
(F) POSTAL CODE (ZIP) : 78701
(G) TELEPHONE: (512) 418-3000 (H) TELEFAX: (512) 474-7577
(ii) TITLE OF INVENTION: INHIBITION OF CHRONIC MYELOGENOUS LEUKEMIC CELL GROWTH BY LIPOSOMAL-ANTISENSE OLIGODEOXY-NUCLEOTIDES TARGETING TO Grb2 OR Crkl
(iii) NUMBER OF SEQUENCES: 7
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS -DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO)
(2) INFORMATION FOR SEQ ID NO : 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1109 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 79..729
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
GCCAGTGAAT TCGGGGGCTC AGCCCTCCTC CCTCCCTTCC CCCTGCTTCA GGCTGCTGAG 60
CACTGAGCAG CGCTCAGA ATG GAA GCC ATC GCC AAA TAT GAC TTC AAA GCT 111
Met Glu Ala lie Ala Lys Tyr Asp Phe Lys Ala
1 5 10
ACT GCA GAC GAC GAG CTG AGC TTC AAA AGG GGG GAC ATC CTC AAG GTT 159 Thr Ala Asp Asp Glu Leu Ser Phe Lys Arg Gly Asp lie Leu Lys Val 15 20 25
TTG AAC GAA GAA TGT GAT CAG AAC TGG TAC AAG GCA GAG CTT AAT GGA 207 Leu Asn Glu Glu Cys Asp Gin Asn Trp Tyr Lys Ala Glu Leu Asn Gly 30 35 40

AAA GAC GGC TTC ATT CCC AAG AAC TAC ATA GAA ATG AAA CCA CAT CCG 255 Lys Asp Gly Phe He Pro Lys Asn Tyr He Glu Met Lys Pro His Pro 45 50 55
TGG TTT TTT GGC AAA ATC CCC AGA GCC AAG GCA GAA GAA ATG CTT AGC 303 Trp Phe Phe Gly Lys He Pro Arg Ala Lys Ala Glu Glu Met Leu Ser 60 65 70 75
AAA CAG CGG CAC GAT GGG GCC TTT CTT ATC CGA GAG AGT GAG AGC GCT 351 Lys Gin Arg His Asp Gly Ala Phe Leu He Arg Glu Ser Glu Ser Ala 80 85 90
CCT GGG GAC TTC TCC CTC TCT GTC AAG TTT GGA AAC GAT GTG CAG CAC 399 Pro Gly Asp Phe Ser Leu Ser Val Lys Phe Gly Asn Asp Val Gin His 95 100 105
TTC AAG GTG CTC CGA GAT GGA GCC GGG AAG TAC TTC CTC TGG GTG GTG 447 Phe Lys Val Leu Arg Asp Gly Ala Gly Lys Tyr Phe Leu Trp Val Val 110 115 120
AAG TTC AAT TCT TTG AAT GAG CTG GTG GAT TAT CAC AGA TCT ACA TCT 495 Lys Phe Asn Ser Leu Asn Glu Leu Val Asp Tyr His Arg Ser Thr Ser 125 130 135
GTC TCC AGA AAC CAG CAG ATA TTC CTG CGG GAC ATA GAA CAG GTG CCA 543 Val Ser Arg Asn Gin Gin He Phe Leu Arg Asp He Glu Gin Val Pro 140 145 150 155
CAG CAG CCG ACA TAC GTC CAG GCC CTC TTT GAC TTT GAT CCC CAG GAG 591 Gin Gin Pro Thr Tyr Val Gin Ala Leu Phe Asp Phe Asp Pro Gin Glu 160 165 170
GAT GGA GAG CTG GGC TTC CGC CGG GGA GAT TTT ATC CAT GTC ATG GAT 639 Asp Gly Glu Leu Gly Phe Arg Arg Gly Asp Phe He His Val Met Asp 175 180 185
AAC TCA GAC CCC AAC TGG TGG AAA GGA GCT TGC CAC GGG CAG ACC GGC 687 Asn Ser Asp Pro Asn Trp Trp Lys Gly Ala Cys His Gly Gin Thr Gly 190 195 200
ATG TTT CCC CGC AAT TAT GTC ACC CCC GTG AAC CGG AAC GTC 729
Met Phe Pro Arg Asn Tyr Val Thr Pro Val Asn Arg Asn Val 205 210 215
TAAGAGTCAA GAAGCAATTA TTTAAAGAAA GTGAAAAATG TAAAACACAT ACAAAAGAAT 789
TAAACCCACA AGCTGCCTCT GACAGCAGCC TGTGAGGGAG TGCAGAACAC CTGGCCGGGT 849
CACCCTGTGA CCCTCTCACT TTGGTTGGAA CTTTAGGGGG TGGGAGGGGG CGTTGGATTT 909
AAAAATGCCA AAACTTACCT ATAAATTAAG AAGAGTTTTT ATTACAAATT TTCACTGCTG 969
CTCCTCTTTC CCCTCCTTTG TCTTTTTTTT CATCCTTTTT TCTCTTCTGT CCATCAGTGC 1029

ATGACGTTTA AGGCCACGTA TAGTCCTAGC TGACGCCAAT AATAAAAAAC AAGAAACCAA 1089
AAAAAAAAAA CCCGAATTCA 1109
(2) INFORMATION FOR SEQ ID NO : 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 217 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Met Glu Ala He Ala Lys Tyr Asp Phe Lys Ala Thr Ala Asp Asp Glu 1 5 10 15
Leu Ser Phe Lys Arg Gly Asp He Leu Lys Val Leu Asn Glu Glu Cys 20 25 30
Asp Gin Asn Trp Tyr Lys Ala Glu Leu Asn Gly Lys Asp Gly Phe He 35 40 45
Pro Lys Asn Tyr He Glu Met Lys Pro His Pro Trp Phe Phe Gly Lys 50 55 60
He Pro Arg Ala Lys Ala Glu Glu Met Leu Ser Lys Gin Arg His Asp 65 70 75 80
Gly Ala Phe Leu He Arg Glu Ser Glu Ser Ala Pro Gly Asp Phe Ser 85 90 95
Leu Ser Val Lys Phe Gly Asn Asp Val Gin His Phe Lys Val Leu Arg 100 105 110
Asp Gly Ala Gly Lys Tyr Phe Leu Trp Val Val Lys Phe Asn Ser Leu 115 120 125
Asn Glu Leu Val Asp Tyr His Arg Ser Thr Ser Val Ser Arg Asn Gin 130 135 140
Gin He Phe Leu Arg Asp He Glu Gin Val Pro Gin Gin Pro Thr Tyr 145 150 155 160
Val Gin Ala Leu Phe Asp Phe Asp Pro Gin Glu Asp Gly Glu Leu Gly 165 170 175
Phe Arg Arg Gly Asp Phe He His Val Met Asp Asn Ser Asp Pro Asn 180 185 190
Trp Trp Lys Gly Ala Cys His Gly Gin Thr Gly Met Phe Pro Arg Asn 195 200 205
Tyr Val Thr Pro Val Asn Arg Asn Val 210 215

(2) INFORMATION FOR SEQ ID NO : 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1881 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 510..1418
( i) SEQUENCE DESCRIPTION: SEQ ID NO : 3:
CGGAGGGGGA GGTGGCTGCC GCTTCTCCCG CGTCCGCCAT TTTGTTGCTG TGGCTATTGG 60
GAACAAGCTG GGCAAAAGCA CCCCGGAGGC GCGACGCTCC TTCGAGTTCG GTGCCTCGTG 120
TGACGGCGGG GGTCGGTGAA GACCCGTCGA GCTGCGGCGC CGGCGCGTTC CAGGCCGGGA 180
GTCACTGGAG GCACCCCTGG GACGCCGAGC AGCCCGAGAA CCCCGGGGTG GCCTCCGCTG 240
CGGCTCGGGT TTGCCTGCCC CGACCCCCCG GCTCTGCCGT GCATTCCCGG GCGGCTCTCT 300
CCGTGTGGCG GCCCCGGAGC AGGCGGGCGG CGTCGGAGGA TGCTGCGGGC CCGGAGCCGA 360
GAGGAAAGTG CTGGCCCAGC CCTCTGAGCG CTCCTCGAGG TGTGCGAGAG GCCCTTCCTC 420
GGCCCCAAAG CCGTCTGCCG GGCTAAGGCG TGCAGAGCAG GCGAGGACAG CCGCCGCCCC 480
TACCGCCGCA GAGTCCCCGG TCCAACACC ATG TCC TCC GCC AGG TTC GAC TCC 533
Met Ser Ser Ala Arg Phe Asp Ser 1 5
TCG GAC CGC TCC GCC TGG TAT ATG GGG CCG GTG TCT CGC CAG GAG GCG 581 Ser Asp Arg Ser Ala Trp Tyr Met Gly Pro Val Ser Arg Gin Glu Ala 10 15 20
CAG ACC CGG CTC CAG GGC CAG CGC CAC GGT ATG TTC CTC GTC CGC GAT 629 Gin Thr Arg Leu Gin Gly Gin Arg His Gly Met Phe Leu Val Arg Asp 25 30 35 40
TCT TCC ACC TGC CCT GGG GAC TAT GTG CTG TCG GTG TCC GAG AAC TCG 677 Ser Ser Thr Cys Pro Gly Asp Tyr Val Leu Ser Val Ser Glu Asn Ser 45 50 55
CGG GTC TCC CAC TAC ATT ATC AAC TCG CTG CCC AAC CGC CGT TTT AAG 725 Arg Val Ser His Tyr He He Asn Ser Leu Pro Asn Arg Arg Phe Lys 60 65 70
ATC GGG GAC CAG GAA TTT GAC CAT TTG CCG GCC CTG CTG GAG TTT TAC 773 He Gly Asp Gin Glu Phe Asp His Leu Pro Ala Leu Leu Glu Phe Tyr 75 80 85

AAG ATC CAC TAC CTG GAC ACC ACC ACC CTC ATC GAG CCT GCG CCC AGG 821
Lys He His Tyr Leu Asp Thr Thr Thr Leu He Glu Pro Ala Pro Arg 90 95 100
TAT CCA AGC CCA CCA ATG GGA TCT GTC TCA GCA CCC AAC CTG CCT ACA 869
Tyr Pro Ser Pro Pro Met Gly Ser Val Ser Ala Pro Asn Leu Pro Thr
105 110 115 120
GCA GAA GAT AAC CTG GAA TAT GTA CGG ACT CTG TAT GAT TTT CCT GGG 917
Ala Glu Asp Asn Leu Glu Tyr Val Arg Thr Leu Tyr Asp Phe Pro Gly 125 130 135
AAT GAT GCC GAA GAC CTG CCC TTT AAA AAG GGT GAG ATC CTA GTG ATA 965
Asn Asp Ala Glu Asp Leu Pro Phe Lys Lys Gly Glu He Leu Val He 140 145 150
ATA GAG AAG CCT GAA GAA CAG TGG TGG AGT GCC CGG AAC AAG GAT GGC 1013
He Glu Lys Pro Glu Glu Gin Trp Trp Ser Ala Arg Asn Lys Asp Gly 155 160 165
CGG GTT GGG ATG ATT CCT GTC CCT TAT GTC GAA AAG CTT GTG AGA TCC 1061
Arg Val Gly Met He Pro Val Pro Tyr Val Glu Lys Leu Val Arg Ser 170 175 180
TCA CCA CAC GGA AAG CAT GGA AAT AGG AAT TCC AAC AGT TAT GGG ATC 1109
Ser Pro His Gly Lys His Gly Asn Arg Asn Ser Asn Ser Tyr Gly He
185 190 195 200
CCA GAA CCT GCT CAT GCA TAC GCT CAA CCT CAG ACC ACA ACT CCT CTA 1157
Pro Glu Pro Ala His Ala Tyr Ala Gin Pro Gin Thr Thr Thr Pro Leu 205 210 215
CCT GCA GTT TCC GGT TCT CCT GGG GCA GCA ATC ACC CCT TTG CCA TCC 1205
Pro Ala Val Ser Gly Ser Pro Gly Ala Ala He Thr Pro Leu Pro Ser 220 225 230
ACA CAG AAT GGA CCT GTC TTT GCG AAA GCA ATC CAG AAA AGA GTA CCC 1253
Thr Gin Asn Gly Pro Val Phe Ala Lys Ala He Gin Lys Arg Val Pro 235 240 245
TGT GCT TAT GAC AAG ACT GCC TTG GCA TTA GAG GTT GGT GAC ATC GTG 1301
Cys Ala Tyr Asp Lys Thr Ala Leu Ala Leu Glu Val Gly Asp He Val 250 255 260
AAA GTC ACA AGG ATG AAT ATA AAT GGC CAG TGG GAA GGC GAA GTG AAC 13 9 Lys Val Thr Arg Met Asn He Asn Gly Gin Trp Glu Gly Glu Val Asn
265 270 275 280
GGG CGC AAA GGG CTT TTC CCC TTT ACG CAC GTC AAA ATC TTT GAC CCT 1397
Gly Arg Lys Gly Leu Phe Pro Phe Thr His Val Lys He Phe Asp Pro 285 290 295
CAA AAC CCA GAT GAA AAC GAG TGATTGCTGT TGCCCTGTTT CCTGCTGCTT 1448 Gin Asn Pro Asp Glu Asn Glu 300

TGTTGTTCTG CCTGTCCTAG TCTCCTTTGA AGTGGGAAAG CATTTTCTCT CATAGGCAAG 1508
TCACACTGCA TTGCCGAAGT CCAGCTTTCT GCAGACTGGC AGTCGCACAC ACATTTGGAA 1568
TGCACACAGC GGCTGCCTCC TGATGTTTGT ATCATAGTCG TATTGTGCAA AGAGTAGCCG 1628
ATTTTAGAGT TCTTTTGGAT CATAAACTGG AAATACTGAT GGAAGCACAC AAGTGGAGAG 1688
AAGTTGACGT GGAAAGGGTC TTCCTTCTCA TTGCTGCCCG TTTGTACATG GGACTGATTC 1748
TGTCGTGTTC ACCAGAGAAA GCTTGAGGCC ATGGCGAGAT ACTGCATGTT TGCTGTTCCA 1808
CAAAGCAGTG GCTTAGCTGC CATCTTGCTT TTCTTTGGAC AACAGGAAGT GAACCTTAAG 1868
GAAGAGAGAA TTC 1881
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 303 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4:
Met Ser Ser Ala Arg Phe Asp Ser Ser Asp Arg Ser Ala Trp Tyr Met 1 5 10 15
Gly Pro Val Ser Arg Gin Glu Ala Gin Thr Arg Leu Gin Gly Gin Arg 20 25 30
His Gly Met Phe Leu Val Arg Asp Ser Ser Thr Cys Pro Gly Asp Tyr 35 40 45
Val Leu Ser Val Ser Glu Asn Ser Arg Val Ser His Tyr He He Asn 50 55 60
Ser Leu Pro Asn Arg Arg Phe Lys He Gly Asp Gin Glu Phe Asp His 65 70 75 80
Leu Pro Ala Leu Leu Glu Phe Tyr Lys He His Tyr Leu Asp Thr Thr 85 90 95
Thr Leu He Glu Pro Ala Pro Arg Tyr Pro Ser Pro Pro Met Gly Ser 100 105 110
Val Ser Ala Pro Asn Leu Pro Thr Ala Glu Asp Asn Leu Glu Tyr Val 115 120 125
Arg Thr Leu Tyr Asp Phe Pro Gly Asn Asp Ala Glu Asp Leu Pro Phe 130 135 140

Lys Lys Gly Glu He Leu Val He He Glu Lys Pro Glu Glu Gin Trp 145 150 155 160
Trp Ser Ala Arg Asn Lys Asp Gly Arg Val Gly Met He Pro Val Pro 165 170 175
Tyr Val Glu Lys Leu Val Arg Ser Ser Pro His Gly Lys His Gly Asn 180 185 190
Arg Asn Ser Asn Ser Tyr Gly He Pro Glu Pro Ala His Ala Tyr Ala 195 200 205
Gin Pro Gin Thr Thr Thr Pro Leu Pro Ala Val Ser Gly Ser Pro Gly 210 215 220
Ala Ala He Thr Pro Leu Pro Ser Thr Gin Asn Gly Pro Val Phe Ala 225 230 235 240
Lys Ala He Gin Lys Arg Val Pro Cys Ala Tyr Asp Lys Thr Ala Leu 245 250 255
Ala Leu Glu Val Gly Asp He Val Lys Val Thr Arg Met Asn He Asn 260 265 270
Gly Gin Trp Glu Gly Glu Val Asn Gly Arg Lys Gly Leu Phe Pro Phe 275 280 285
Thr His Val Lys He Phe Asp Pro Gin Asn Pro Asp Glu Asn Glu 290 295 300
(2) INFORMATION FOR SEQ ID NO : 5:
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDΞDNESS : single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: ATATTTGGCG ATGGCTTC 18
(2) INFORMATION FOR SEQ ID NO : 6:
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 6: GTCGAACCGG CGGAGGA 17

(2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7: GAAGGGCTTC TGCGTC 16

Claims (26)

1. A composition comprising a polynucleotide that hybridizes to the translation initiation site of a Grb2-encoding polynucleotide.

2. A composition comprising a polynucleotide that hybridizes to the translation initiation site of a Crkl-encoding polynucleotide.

3. The composition of claim 1, wherein said polynucleotide is an oligonucleotide having a length of 8-50 bases.

4. The composition of claim 2, wherein said polynucleotide is an oligonucleotide having a length of 8-50 bases.

5. The composition of claim 1, wherein the polynucleotide is an oligonucleotide having the sequence ATATTTGGCGATGGCTTC (SEQ ID NO: 5).

6. The composition of claim 2, wherein the polynucleotide is an oligonucleotide having the sequence GTCGAACCGGCGGAGGA (SEQ ID NO: 6).

7. The composition of claim 1 , further comprising a liposome in which said
polynucleotide is encapsulated.

8. The composition of claim 2, further comprising a liposome in which said polynucleotide is encapsulated.

9. The composition of claim 7, wherein said liposome comprises the lipid dioleoylphosphatidylcholine.

10. The composition of claim 8, wherein said liposome comprises the lipid dioleoylphosphatidylcholine.

11. A composition comprising (i) a polynucleotide that hybridizes to a Grb2- encoding polynucleotide or (ii) a polynucleotide that hybridizes to a Crkl-encoding polynucleotide.

12. The composition of claim 11, further comprising a polynucleotide that hybridizes to a bcr-abl-encoding polynucleotide.

13. A composition comprising an expression construct that encodes a first polynucleotide that hybridizes to the translation start site of a Grb2-encoding polynucleotide, wherein said first polynucleotide is under the control of a promoter that is active in eukaryotic cells.

14. A composition comprising an expression construct that encodes a first polynucleotide that hybridizes to the translation start site of a Crkl-encoding polynucleotide, wherein said first polynucleotide is under the control of a promoter that is active in eukaryotic cells.

15. A method for inhibiting proliferation of a cancer cell comprising contacting said cancer cell with a composition comprising at least (i) a polynucleotide that hybridizes to the translation start site of a Grb2 nucleic acid or (ii) a polynucleotide that hybridizes to the translation start site of a Crkl nucleic acid.

16. The method of claim 15, wherein said polynucleotides are oligonucleotides having a length of 8-50 bases.

17. The method of claim 16, wherein said composition further comprises a polynucleotide that hybridizes to a bcr-abl nucleic acid.

18. The method of claim 17, wherein said composition comprises both (i) a polynucleotide that hybridizes to the translation start site of a Grb2 nucleic acid or (ii) a polynucleotide that hybridizes to the translation start site of a Crkl nucleic acid.

19. The method of claim 16, wherein said cancer cell is a leukemia cell.

20. The method of claim 19, wherein said cancer cell is a chronic myelogenous leukemia cell.

21. The method of claim 16, wherein said composition further comprises a liposome in which said polynucleotide is encapsulated.

22. The method of claim 16, wherein said contacting takes place in a patient.

23. The method of claim 22, wherein said patient is a human.

24. The method of claim 22, wherein said composition is delivered to said human in a volume of 0.50- 10.0 ml per dose.

25. The method of claim 22, wherein said composition is delivered to said human in an amount of 5-30 mg polynucleotide per mZ.

26. The method of claim 25, wherein said composition is administered three times per week for eight weeks.

AU35694/97A
1996-07-08
1997-07-08
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1

Ceased

AU740289B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

US08/679437

1996-07-08

US08/679,437

US7309692B1
(en)

1996-07-08
1996-07-08
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1

PCT/US1997/010101

WO1998001547A1
(en)

1996-07-08
1997-07-08
INHIBITION OF CHRONIC MYELOGENOUS LEUKEMIC CELL GROWTH BY LIPOSOMAL-ANTISENSE OLIGODEOXY-NUCLEOTIDES TARGETING TO Grb2 OR Crk1

Publications (2)

Publication Number
Publication Date

AU3569497A
true

AU3569497A
(en)

1998-02-02

AU740289B2

AU740289B2
(en)

2001-11-01

Family
ID=24726909
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU35694/97A
Ceased

AU740289B2
(en)

1996-07-08
1997-07-08
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1

Country Status (9)

Country
Link

US
(3)

US7309692B1
(en)

EP
(2)

EP0912729B1
(en)

JP
(1)

JP2000514438A
(en)

AT
(2)

ATE383422T1
(en)

AU
(1)

AU740289B2
(en)

CA
(2)

CA2259144C
(en)

DE
(2)

DE69738459T2
(en)

ES
(2)

ES2299536T3
(en)

WO
(1)

WO1998001547A1
(en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

WO2001062911A2
(en)

*

2000-02-24
2001-08-30
Ribozyme Pharmaceuticals, Inc.
Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses

JP2008536874A
(en)

2005-04-15
2008-09-11
ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム

Delivery of siRNA by neutral lipid composition

US8900627B2
(en)

*

2008-06-06
2014-12-02
Mirna Therapeutics, Inc.
Compositions for the in vivo delivery of RNAi agents

BRPI0915718A2
(en)

*

2008-06-20
2017-06-20
Univ Texas

crkl steering peptides

CN108291227A
(en)

2015-10-14
2018-07-17
拜奥-帕斯控股股份有限公司
For Liposomal formulation to ethyoxyl nucleic acid

AU2017325971A1
(en)

*

2016-09-16
2019-04-11
Bio-Path Holdings, Inc.
Combination therapy with liposomal antisense oligonucleotides

BR112019021771A2
(en)

2017-04-19
2020-05-05
Bio Path Holdings Inc

p-ethoxy nucleic acids for stat3 inhibition

Family Cites Families (49)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

CH621479A5
(en)

1977-08-05
1981-02-13
Battelle Memorial Institute

US4394448A
(en)

1978-02-24
1983-07-19
Szoka Jr Francis C
Method of inserting DNA into living cells

US4469863A
(en)

1980-11-12
1984-09-04
Ts O Paul O P
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof

FR2540122B1
(en)

1983-01-27
1985-11-29
Centre Nat Rech Scient

NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION

US5202429A
(en)

1986-07-09
1993-04-13
The Wistar Institute
DNA molecules having human BCL-2 gene sequences

US5094785A
(en)

1986-12-10
1992-03-10
Ciba Corning Diagnostics Corp.
Process for stabilizing liposomes

US4837028A
(en)

1986-12-24
1989-06-06
Liposome Technology, Inc.
Liposomes with enhanced circulation time

US4920016A
(en)

1986-12-24
1990-04-24
Linear Technology, Inc.
Liposomes with enhanced circulation time

US4904582A
(en)

1987-06-11
1990-02-27
Synthetic Genetics
Novel amphiphilic nucleic acid conjugates

US5188897A
(en)

1987-10-22
1993-02-23
Temple University Of The Commonwealth System Of Higher Education
Encapsulated 2′,5′-phosphorothioate oligoadenylates

US5225326A
(en)

*

1988-08-31
1993-07-06
Research Development Foundation
One step in situ hybridization assay

US5831066A
(en)

1988-12-22
1998-11-03
The Trustees Of The University Of Pennsylvania
Regulation of bcl-2 gene expression

US5734033A
(en)

1988-12-22
1998-03-31
The Trustees Of The University Of Pennsylvania
Antisense oligonucleotides inhibiting human bcl-2 gene expression

WO1990012595A1
(en)

1989-04-18
1990-11-01
Vestar, Inc.
Liposomal targeting of ischemic tissue

CA2033725C
(en)

1990-01-24
2001-05-29
Folker Pittrof
Pharmaceutical and cosmetic compositions containing a salt of cholanic acid

US5279833A
(en)

1990-04-04
1994-01-18
Yale University
Liposomal transfection of nucleic acids into animal cells

US5665710A
(en)

1990-04-30
1997-09-09
Georgetown University
Method of making liposomal oligodeoxynucleotide compositions

DE59108644D1
(en)

1990-07-02
1997-05-07
Hoechst Ag

Oligonucleotide analogs with terminal 3’-3 ‘or. 5’-5 ‘internucleotide linkages

US5378825A
(en)

1990-07-27
1995-01-03
Isis Pharmaceuticals, Inc.
Backbone modified oligonucleotide analogs

EP0590090A4
(en)

*

1991-06-18
1995-04-12
Univ Temple
SELECTIVE INHIBITION OF LEUKEMIC CELL PROLIFERATION BY -i(BCR-ABL) ANTISENSE OLIGONUCLEOTIDES.

US5585479A
(en)

*

1992-07-24
1996-12-17
The United States Of America As Represented By The Secretary Of The Navy
Antisense oligonucleotides directed against human ELAM-I RNA

US6001992A
(en)

1999-01-07
1999-12-14
Isis Pharmaceuticals Inc.
Antisense modulation of novel anti-apoptotic bcl-2-related proteins

US6015886A
(en)

1993-05-24
2000-01-18
Chemgenes Corporation
Oligonucleotide phosphate esters

FR2710074B1
(en)

1993-09-15
1995-12-08
Rhone Poulenc Rorer Sa

GRB3-3 gene, its variants and their uses.

EP0721503A1
(en)

1993-09-28
1996-07-17
The General Hospital Corporation
USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE $g(b)/A4 AMYLOID-INDUCED MORPHOLOGY

US5510239A
(en)

*

1993-10-18
1996-04-23
Isis Pharmaceuticals, Inc.
Oligonucleotide modulation of multidrug resistance-associated protein

CA2113494A1
(en)

1994-01-14
1995-07-15
Lorri Puil
Method for assaying for substances which affect bcr-abl mediated transformation

US5651981A
(en)

1994-03-29
1997-07-29
Northwestern University
Cationic phospholipids for transfection

US5667981A
(en)

1994-05-13
1997-09-16
Childrens Hospital Of Los Angeles
Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein

US5696248A
(en)

1994-06-15
1997-12-09
Hoechst Aktiengesellschaft
3’-modified oligonucleotide derivatives

US5908635A
(en)

1994-08-05
1999-06-01
The United States Of America As Represented By The Department Of Health And Human Services
Method for the liposomal delivery of nucleic acids

US5734039A
(en)

*

1994-09-15
1998-03-31
Thomas Jefferson University
Antisense oligonucleotides targeting cooperating oncogenes

DE69636339T2
(en)

1995-06-01
2007-07-19
Kishimoto, Tadamitsu, Tondabayashi

GROWTH INHIBITOR AGAINST LEUKEMIC CELLS CONTAINING ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST THE WILMS TUMORGEN

US6326487B1
(en)

1995-06-05
2001-12-04
Aventis Pharma Deutschland Gmbh
3 modified oligonucleotide derivatives

IL122290A0
(en)

1995-06-07
1998-04-05
Inex Pharmaceuticals Corp
Lipid-nucleic acid complex its preparation and use

US5705385A
(en)

1995-06-07
1998-01-06
Inex Pharmaceuticals Corporation
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer

AU705644B2
(en)

1995-08-01
1999-05-27
Novartis Ag
Liposomal oligonucleotide compositions

US6120794A
(en)

1995-09-26
2000-09-19
University Of Pittsburgh
Emulsion and micellar formulations for the delivery of biologically active substances to cells

WO1997020573A1
(en)

1995-12-04
1997-06-12
Smithkline Beecham Corporation
Growth factor receptor-binding protein 2 homolog

US5874224A
(en)

1997-03-11
1999-02-23
Incyte Pharmaceuticals, Inc.
Growth factor receptor binding protein

US6126965A
(en)

1997-03-21
2000-10-03
Georgetown University School Of Medicine
Liposomes containing oligonucleotides

GB9711919D0
(en)

1997-06-09
1997-08-06
Ciba Geigy Ag
Oligonucleotide derivatives

ATE255882T1
(en)

1997-06-23
2003-12-15
Sequus Pharm Inc

LIPOSOME ENCLOSED POLYNUCLEOTIDE COMPOSITION AND METHOD

US6277981B1
(en)

1997-07-03
2001-08-21
Thomas Jefferson University
Method for design and selection of efficacious antisense oligonucleotides

US6136965A
(en)

1998-07-02
2000-10-24
The Regents Of The University Of California
Deoxynucleic alkyl and alkoxy thiourea compounds

US6211162B1
(en)

1998-12-30
2001-04-03
Oligos Etc. Inc.
Pulmonary delivery of protonated/acidified nucleic acids

US6211349B1
(en)

1998-12-30
2001-04-03
Oligos Etc., Inc.
Protonated/acidified nucleic acids and methods of use

US6323487B1
(en)

*

1999-01-26
2001-11-27
Delphi Technologies, Inc.
IR optical position sensor system

US7795232B1
(en)

2000-08-25
2010-09-14
Genta Incorporated
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

1996

1996-07-08
US
US08/679,437
patent/US7309692B1/en
not_active
Expired – Fee Related

1997

1997-07-08
DE
DE69738459T
patent/DE69738459T2/en
not_active
Expired – Lifetime

1997-07-08
EP
EP97932167A
patent/EP0912729B1/en
not_active
Expired – Lifetime

1997-07-08
AU
AU35694/97A
patent/AU740289B2/en
not_active
Ceased

1997-07-08
ES
ES02001271T
patent/ES2299536T3/en
not_active
Expired – Lifetime

1997-07-08
DE
DE69736290T
patent/DE69736290T2/en
not_active
Expired – Lifetime

1997-07-08
AT
AT02001271T
patent/ATE383422T1/en
not_active
IP Right Cessation

1997-07-08
EP
EP02001271A
patent/EP1234876B1/en
not_active
Expired – Lifetime

1997-07-08
AT
AT97932167T
patent/ATE332369T1/en
not_active
IP Right Cessation

1997-07-08
CA
CA2259144A
patent/CA2259144C/en
not_active
Expired – Fee Related

1997-07-08
CA
CA2741501A
patent/CA2741501A1/en
not_active
Abandoned

1997-07-08
WO
PCT/US1997/010101
patent/WO1998001547A1/en
active
IP Right Grant

1997-07-08
JP
JP10505197A
patent/JP2000514438A/en
active
Pending

1997-07-08
ES
ES97932167T
patent/ES2268731T3/en
not_active
Expired – Lifetime

2002

2002-12-20
US
US10/327,509
patent/US7220853B2/en
not_active
Expired – Fee Related

2007

2007-04-03
US
US11/696,015
patent/US7923548B2/en
not_active
Expired – Fee Related

Also Published As

Publication number
Publication date

EP0912729A1
(en)

1999-05-06

JP2000514438A
(en)

2000-10-31

US20070238686A1
(en)

2007-10-11

WO1998001547A1
(en)

1998-01-15

DE69738459T2
(en)

2008-12-24

DE69736290D1
(en)

2006-08-17

ES2299536T3
(en)

2008-06-01

EP1234876B1
(en)

2008-01-09

ES2268731T3
(en)

2007-03-16

US7309692B1
(en)

2007-12-18

CA2741501A1
(en)

1998-01-15

US7923548B2
(en)

2011-04-12

ATE383422T1
(en)

2008-01-15

DE69738459D1
(en)

2008-02-21

US20030153526A1
(en)

2003-08-14

CA2259144C
(en)

2011-09-20

DE69736290T2
(en)

2007-07-05

EP0912729B1
(en)

2006-07-05

AU740289B2
(en)

2001-11-01

ATE332369T1
(en)

2006-07-15

CA2259144A1
(en)

1998-01-15

US7220853B2
(en)

2007-05-22

EP1234876A1
(en)

2002-08-28

Similar Documents

Publication
Publication Date
Title

CA2266584C
(en)

2009-12-08

Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides

US7285288B1
(en)

2007-10-23

Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides

US5786213A
(en)

1998-07-28

Inhibition of endogenous gastrin expression for treatment of colorectal cancer

US7923548B2
(en)

2011-04-12

Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1

AU724324B2
(en)

2000-09-14

p16 expression constructs and their application in cancer therapy

AU745591B2
(en)

2002-03-21

Use of PEA3 in tumor suppression

US7704962B1
(en)

2010-04-27

Small oligonucleotides with anti-tumor activity

US6482803B1
(en)

2002-11-19

Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A

WO1997016547A9
(en)

1997-07-10

ADENOVIRUS-ANTISENSE K-ras EXPRESSION VECTORS AND THEIR APPLICATION IN CANCER THERAPY

WO1997016547A1
(en)

1997-05-09

ADENOVIRUS-ANTISENSE K-ras EXPRESSION VECTORS AND THEIR APPLICATION IN CANCER THERAPY

AU5001099A
(en)

2000-02-07

Repression of cell transformation with human pea3

WO1996038556A2
(en)

1996-12-05

Deltap62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer

Legal Events

Date
Code
Title
Description

2002-02-28
FGA
Letters patent sealed or granted (standard patent)

2002-07-04
DA3
Amendments made section 104

Free format text:
THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE PATENTEE TO READ BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

2002-08-01
DA3
Amendments made section 104

Free format text:
THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT S NAME TO READ: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Download PDF in English